Jan 8 Catalyst Pharmaceutical Partners Inc
said a study showed its experimental drug to treat a
rare autoimmune disorder did not have an adverse effect on the
heart rate of patients.
Catalyst's shares rose 14 percent to $2.31 before the bell.
The company also said the drug, Firdapse, did not affect the
time the heart takes to recharge after each beat. If the time is
prolonged, the risk of developing irregular heart rhythms
increases, the company said.
The safety study, which compared Firdapse to a placebo in 59
healthy volunteers, was required by the U.S. Food and Drug
Administration as part of Catalyst's marketing application.
Firdapse is being tested in a late-stage trial in patients
with Lambert-Eaton Myasthenic Syndrome, a disorder that causes
Firdapse is approved in the European Union, where it is
marketed by BioMarin Pharmaceutical Inc.
(Reporting By Vrinda Manocha in Bangalore; Editing by Saumyadeb